S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

NASDAQ:ARVN - Arvinas Stock Price, Forecast & News

$48.54
+0.54 (+1.13 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$47.56
Now: $48.54
$50.94
50-Day Range
$44.34
MA: $50.00
$54.50
52-Week Range
$14.06
Now: $48.54
$54.95
Volume241,300 shs
Average Volume294,213 shs
Market Capitalization$1.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.69
Arvinas, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARVN
CUSIPN/A
CIKN/A
Phone203-535-1456

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.32 million
Book Value$4.22 per share

Profitability

Net Income$-41,480,000.00
Net Margins-157.34%

Miscellaneous

Employees83
Market Cap$1.64 billion
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive ARVN News and Ratings via Email

Sign-up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.


Arvinas (NASDAQ:ARVN) Frequently Asked Questions

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

How were Arvinas' earnings last quarter?

Arvinas Inc (NASDAQ:ARVN) issued its quarterly earnings results on Monday, November, 4th. The company reported $0.21 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.67. The company had revenue of $30.05 million for the quarter, compared to the consensus estimate of $11.42 million. Arvinas had a negative return on equity of 31.57% and a negative net margin of 157.34%. View Arvinas' Earnings History.

When is Arvinas' next earnings date?

Arvinas is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Arvinas.

What price target have analysts set for ARVN?

10 equities research analysts have issued twelve-month target prices for Arvinas' stock. Their forecasts range from $22.00 to $75.00. On average, they expect Arvinas' stock price to reach $50.00 in the next year. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for Arvinas.

What is the consensus analysts' recommendation for Arvinas?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arvinas.

Has Arvinas been receiving favorable news coverage?

News coverage about ARVN stock has been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arvinas earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Arvinas.

Are investors shorting Arvinas?

Arvinas saw a decrease in short interest during the month of February. As of February 14th, there was short interest totalling 1,590,000 shares, a decrease of 25.4% from the January 30th total of 2,130,000 shares. Based on an average daily trading volume, of 388,200 shares, the days-to-cover ratio is currently 4.1 days. Approximately 7.0% of the company's stock are sold short. View Arvinas' Current Options Chain.

Who are some of Arvinas' key competitors?

What other stocks do shareholders of Arvinas own?

Who are Arvinas' key executives?

Arvinas' management team includes the folowing people:
  • Dr. John G. Houston Ph.D., CEO, Pres & Director (Age 59)
  • Mr. Sean A. Cassidy, CFO & Treasurer (Age 49)
  • Dr. Ian Taylor, Chief Scientific Officer (Age 56)
  • Dr. Craig M. Crews, Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
  • Dr. Andrew Crew, Chief Technology Officer (Age 54)

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Canaan Partners IX LLC (13.30%), RA Capital Management L.P. (10.88%), 5AM Venture Management LLC (4.08%), EcoR1 Capital LLC (3.97%), FMR LLC (2.25%) and State Street Corp (1.30%). Company insiders that own Arvinas stock include Bradley Albert Margus, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am. View Institutional Ownership Trends for Arvinas.

Which major investors are selling Arvinas stock?

ARVN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Schonfeld Strategic Advisors LLC, Barclays PLC, Oregon Public Employees Retirement Fund, Chicago Equity Partners LLC, UBS Group AG, Matisse Capital and Advisory Research Inc.. Company insiders that have sold Arvinas company stock in the last year include Ian Taylor, Sean A Cassidy and Ventures Iii LP 5Am. View Insider Buying and Selling for Arvinas.

Which major investors are buying Arvinas stock?

ARVN stock was bought by a variety of institutional investors in the last quarter, including Canaan Partners IX LLC, RA Capital Management L.P., 5AM Venture Management LLC, EcoR1 Capital LLC, Perceptive Advisors LLC, Boxer Capital LLC, ArrowMark Colorado Holdings LLC and Pictet Asset Management Ltd.. Company insiders that have bought Arvinas stock in the last two years include Bradley Albert Margus, Ian Taylor, James E Flynn, Liam Ratcliffe, Sean A Cassidy and Timothy M Shannon. View Insider Buying and Selling for Arvinas.

How do I buy shares of Arvinas?

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $48.54.

How big of a company is Arvinas?

Arvinas has a market capitalization of $1.64 billion and generates $14.32 million in revenue each year. The company earns $-41,480,000.00 in net income (profit) each year or ($25.45) on an earnings per share basis. Arvinas employs 83 workers across the globe.View Additional Information About Arvinas.

What is Arvinas' official website?

The official website for Arvinas is http://www.arvinas.com/.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]


MarketBeat Community Rating for Arvinas (NASDAQ ARVN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  58 (Thanks for Voting!)
Underperform Votes:  75 (Thanks for Voting!)
Total Votes:  133
MarketBeat's community ratings are surveys of what our community members think about Arvinas and other stocks. Vote "Outperform" if you believe ARVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel